Lilly Opens Infusion Centers for High-Risk Hoosiers

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is partnering with local
health systems to launch dedicated infusion centers throughout the state.
The centers are designed to provide residents with access to COVID-19
treatments such as Lilly’s FDA-authorized antibody therapies.

Lilly is partnering with Ascension St. Vincent, Community Health Network,
Eskenazi Health, Franciscan Health, Saint Joseph Health System, Beacon
Health System and Goshen Health System on the infusion centers.

To date, Lilly says the centers have delivered antibody treatments to more
than 1,700 Hoosiers at high-risk of contracting COVID-19.

“Throughout the implementation of our COVID-19 antibody clinical development
program, we have identified multiple approaches to address many of the
challenges this virus has presented, including complexities experienced with
intravenous administration during the pandemic,” said Rob Metcalf, senior
vice president of clinical development at Lilly. “We are pleased to share
our insights with the goal of enabling health systems to quickly provide
access to the COVID-19 antibody therapies needed to fight this devastating
virus in high-risk symptomatic patients.”

The infusion centers are located at:

* Northern Indiana: COVID Infusion Center 60205 Bodnar Blvd.
Mishawaka, IN 46544
* Central Indiana: Neurodiagnostic Center 5435 East 16th Street, 4th
floor, Indianapolis, IN 46218
* Southern Indiana: Ascension St. Vincent Evansville 100 St Mary’s
Epworth Crossing, Evansville, IN 47630

Lilly says it is sharing insights gathered from the infusion centers with
governments, health systems and other stakeholders to help other locations
open to serve more patients.